Yen L, Woo A, Christopoulopoulos G, Batist G, Panasci L, Roy R, Mitra S, Alaoui-Jamali M A
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada.
Mutat Res. 1995 Nov;337(3):179-89. doi: 10.1016/0921-8777(95)00022-c.
Human breast carcinoma (MCF7-MLNr) cells resistant to the bifunctional drugs L-phenylalanine mustard (L-PAM, 5-fold resistance), mechlorethamine (9-fold), cisplatin (3-fold), and BCNU (3-fold) were used to investigate the role of DNA repair in the development of resistance to alkylating agents. We have previously shown that neither L-PAM transport and metabolism nor glutathione-associated enzymes were altered in MCF7-MLNr cells, compared to the sensitive cells MCF7-WT. This study shows that treatment of pRSV-CAT plasmid with L-PAM at concentrations up to 1 microM proportionally inhibit the expression of chloramphenicol acetyl transferase (CAT) activity, while higher concentrations abolished CAT activity. pRSV-CAT reactivation was significantly increased when plasmid was transfected into MCF7-MLNr cells, compared to MCF7-WT cells. This indicates that resistant cells have more efficient capacity to recognize and repair L-PAM induced DNA damage. The mRNA expression of DNA nucleotide excision repair genes ERCC1, XPD (ERCC2), XPB (ERCC3), and polymerase beta was found to be similar in both the MCF7-WT and MCF7-MLNr cells. Western blot analysis also reveals no difference in the expression of ERCC1, AP endonuclease, poly (ADP-ribose) polymerase, and alkyl-N-purine-DNA glycosylase proteins. The lack of correlation between enhanced host cell reactivation capacity in resistant cells, and the expression of these specific DNA repair genes suggests that proteins encoded by these genes are not rate limiting steps for resistance to bi-functional alkylating drugs in human breast cancer cells.
对双功能药物左旋苯丙氨酸氮芥(L-PAM,5倍耐药)、氮芥(9倍)、顺铂(3倍)和卡莫司汀(3倍)耐药的人乳腺癌(MCF7-MLNr)细胞被用于研究DNA修复在对烷化剂耐药性发展中的作用。我们之前已经表明,与敏感细胞MCF7-WT相比,MCF7-MLNr细胞中L-PAM的转运和代谢以及谷胱甘肽相关酶均未改变。本研究表明,用浓度高达1 microM的L-PAM处理pRSV-CAT质粒会成比例地抑制氯霉素乙酰转移酶(CAT)活性的表达,而更高浓度则会消除CAT活性。与MCF7-WT细胞相比,当质粒转染到MCF7-MLNr细胞中时,pRSV-CAT的再激活显著增加。这表明耐药细胞具有更有效的能力来识别和修复L-PAM诱导的DNA损伤。发现DNA核苷酸切除修复基因ERCC1、XPD(ERCC2)、XPB(ERCC3)和聚合酶β的mRNA表达在MCF7-WT和MCF7-MLNr细胞中相似。蛋白质印迹分析也显示ERCC1、AP内切核酸酶、聚(ADP-核糖)聚合酶和烷基-N-嘌呤-DNA糖基化酶蛋白的表达没有差异。耐药细胞中宿主细胞再激活能力增强与这些特定DNA修复基因的表达之间缺乏相关性,这表明这些基因编码的蛋白质不是人乳腺癌细胞对双功能烷化药物耐药的限速步骤。